Investigating how protein processes affect blood vessel health in early pulmonary arterial hypertension.
Official title: Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension
Funded at Brigham and Women's Hospital · NIH-10842357 · Data updated 2026-11-12
This study is looking at how a process called ubiquitination affects the thickening of blood vessels in the lungs, which can lead to early pulmonary arterial hypertension (PAH) and heart problems, with the goal of finding new ways to help patients feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $168,952 |
| NIH project number | 5K08HL151976-05 |
| Project ID | NIH-10842357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage pulmonary arterial hypertension.
✕Less likely to help
Patients with advanced pulmonary arterial hypertension or those who do not have a diagnosis of PAH may not benefit from this research.
What this research studies
This research focuses on understanding the role of ubiquitination in the development of endothelial fibrosis, which is a key factor in early pulmonary arterial hypertension (PAH). The project aims to explore the biochemical processes that lead to vascular remodeling and dysfunction in the lungs, potentially leading to heart failure. Through a combination of laboratory experiments and clinical insights, the research seeks to identify early therapeutic targets that could improve patient outcomes. The principal investigator will receive mentorship from leading experts in the field to ensure a comprehensive approach to the problem.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve the health and longevity of patients with early pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in targeting similar biochemical pathways in vascular diseases, indicating potential for success in this area.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Wertheim, Bradley — Brigham and Women's Hospital
- Study coordinator: Wertheim, Bradley
Related research
Other NIH-funded projects on the same topics.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.